Medical Xpress October 24, 2024
Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D).
Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills. According to the Alzheimer’s Association, nearly 7 million Americans 65 and older are living with the disease, and there are more deaths from Alzheimer’s than breast and prostate cancer combined.
The study, published in Alzheimer’s & Dementia, suggests that T2D patients taking semaglutide had a significantly lower risk of developing Alzheimer’s disease. These results were consistent across different subgroups, including obesity status, gender and age.
Semaglutide, a...
Today's Sponsors
Today's Sponsor